ArticleHuman vaccines & immunotherapeutics2020
Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.
Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Consideration of intersectoral costs and benefits in health economic evaluations of pneumococcal conjugate vaccines: a systematic review.International journal of technology assessment in health care · 2026Pooled it
- Serotype diversity and risk factors for pneumococcal carriage among healthy children in Klang Valley, Malaysia: A pre-vaccination cross-sectional study.IJID regions · 2026Article
- Factors associated with willingness to accept pneumococcal vaccine based on the Health Belief Model among the elderly (≥60 years) living in Klang Valley, Malaysia.Human vaccines & immunotherapeutics · 2025Article
- Article
- Detection of Macrolide-ResistantThe Malaysian journal of medical sciences : MJMS · 2024Article
- A brief history of and future prospects for pneumococcal vaccination in Malaysia.Pneumonia (Nathan Qld.) · 2023Review
- Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.Infectious diseases and therapy · 2023Article
- The Molecular Approaches and Challenges ofPolish journal of microbiology · 2023Review
- Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.Human vaccines & immunotherapeutics · 2022Article
- Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt.Human vaccines & immunotherapeutics · 2022Article
- Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".Infectious diseases and therapy · 2022Article
- Serotype distribution of invasive, non-invasive and carried Streptococcus pneumoniae in Malaysia: a meta-analysis.Pneumonia (Nathan Qld.) · 2021Review
- Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.Human vaccines & immunotherapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumococcal disease is a potentially fatal bacterial infection that is vaccine-preventable. Malaysia has yet to adopt a pneumococcal conjugate vaccine (PCV) into its national immunization program (NIP). In 2016, pneumonia was the 3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.